^
    3d
    Efficacy and Safety of Nintedanib Combined with Radiotherapy in Preventing Radiation Pneumonitis in Patients with Lung Cancer (ChiCTR2500112642)
    P2, N=80, Not yet recruiting, HenanCancerHospital; HenanCancerHospital
    New P2 trial
    |
    nintedanib
    11d
    Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=66, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Nov 2025 --> Aug 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • nintedanib
    12d
    Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. (PubMed, Cell Rep Med)
    In pre-clinical PC, TIMP-1/CISS proves targetable through combined inhibition of upstream kinases with clinically approved drugs trametinib and nintedanib. Collectively, CISS represents a ubiquitous signature of pro-tumor immunoinstruction with actionable diagnostic and therapeutic potential across human cancers.
    Journal
    |
    IL2 (Interleukin 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1)
    |
    Mekinist (trametinib) • nintedanib
    13d
    Nintedanib Attenuates Epidural Fibrosis After Laminectomy in Rats. (PubMed, J Korean Neurosurg Soc)
    By improving the dural structure and reducing key molecules that contribute to scar formation, NIN shows significant promise as a treatment to prevent postoperative epidural adhesions. Future studies with extended follow-up may help clarify its clinical relevance.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta)
    |
    nintedanib
    13d
    PEMBIB: Trial Of Pembrolizumab And Nintedanib (clinicaltrials.gov)
    P1, N=196, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Recruiting --> Completed | Trial completion date: Nov 2028 --> Jan 2026
    Trial completion • Trial completion date • Tumor mutational burden
    |
    Keytruda (pembrolizumab) • nintedanib
    19d
    Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial. (PubMed, JCO Precis Oncol)
    HRD status, KELIM, and TILs are key independent biomarkers in advanced OC. CCNE1 amplifications, although typically associated with platinum resistance, were linked to moderate chemotherapy sensitivity, defining an intermediate prognostic subgroup.
    P2 data • Journal • BRCA Biomarker
    |
    HRD (Homologous Recombination Deficiency) • CCNE1 (Cyclin E1)
    |
    HRD
    |
    nintedanib
    20d
    Breakfree-SSc: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (clinicaltrials.gov)
    P3, N=92, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    New P3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • nintedanib • fludarabine IV • Actemra IV (tocilizumab) • zolacaptagene autoleucel (BMS-986353)
    24d
    Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib (clinicaltrials.gov)
    P1, N=24, Completed, PureTech | Not yet recruiting --> Completed
    Trial completion
    |
    nintedanib
    25d
    The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib (clinicaltrials.gov)
    P=N/A, N=157, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | N=493 --> 157
    Enrollment closed • Enrollment change • HEOR
    |
    nintedanib
    1m
    The tumour immune microenvironment is enriched but suppressed in vestibular schwannoma compared to meningioma: therapeutic implications for NF2-related schwannomatosis. (PubMed, Acta Neuropathol Commun)
    These include bosutinib, sorafenib, mitoxantrone, and nintedanib which are yet to be clinically investigated for vestibular schwannoma or meningioma. Drug repurposing may offer an expedited route to the clinical translation of approved drugs effective for treating both meningioma and vestibular schwannoma to benefit NF2-related schwannomatosis patients.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    sorafenib • bosutinib • nintedanib • mitoxantrone
    2ms
    Unravelling the Crosstalk: Anti-Fibrotic Agents and MAPK Inhibitors in the Treatment of Melanoma. (PubMed, Crit Rev Oncol Hematol)
    Targeting fibrotic pathways such as TGF-β, FGF, and PDGF signalling, with medications like nintedanib and pirfenidone, may help overcome the resistance mechanisms associated with MAPK inhibitor therapy. This review unravels the complex interactions between MAPK inhibitors and anti-fibrotic drugs in the treatment of melanoma, highlighting how they might work together to remodel the TME and overcome treatment resistance. Implementing this combinatorial method could lead to novel approaches for long-term melanoma control and provide a model for anti-fibrotic-based treatments for other solid cancers.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    nintedanib
    2ms
    NINBOST2018: Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=20, Recruiting, University Hospital, Basel, Switzerland | Trial primary completion date: Aug 2025 --> Dec 2026 | Trial completion date: Aug 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    nintedanib